Clinical Trial Update: Dose Escalation of Interleukin-1 (IL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B Virus (HBV) Infected Patients [Phase 1, Phase 2]

View source ↗

Summary

This update describes a dose-escalation trial of Interleukin-7 added to antiviral treatment and vaccination in HBeAg-negative chronic hepatitis B patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Interleukin-7 (interleukin-7)

Snippet

Sponsor: Cytheris SA | Conditions: Chronic Hepatitis B | Phase 1, Phase 2 | Status: UNKNOWN